JP2023548205A - コロナウイルススパイクタンパク質の受容体結合ドメインを含むキメラタンパク質及びその組成物 - Google Patents

コロナウイルススパイクタンパク質の受容体結合ドメインを含むキメラタンパク質及びその組成物 Download PDF

Info

Publication number
JP2023548205A
JP2023548205A JP2023527114A JP2023527114A JP2023548205A JP 2023548205 A JP2023548205 A JP 2023548205A JP 2023527114 A JP2023527114 A JP 2023527114A JP 2023527114 A JP2023527114 A JP 2023527114A JP 2023548205 A JP2023548205 A JP 2023548205A
Authority
JP
Japan
Prior art keywords
hbcag
protein
crbdh6
rbd
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527114A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548205A5 (enExample
Inventor
サンティアゴ、グレイ チネア
デュン、アレハンドロ、ミゲル マーティン
ロチェ、ディアミレ ゴンザレス
フェルナンデス、ミラディス リモンタ
ペレス、エンリケ イグレシアス
ロメロ、モニカ ベケット
ミリアン 、ヘクター サンタナ
ペレラ、ガブリエル、ホタ． マルケス
ラサ、アレクシス ムサッキオ
リコ、アニア カブラレス
ニエト、ゲラルド、エンリケ ギレン
アヴィラ、マルタ アヤラ
バスケス、エウロヒオ ピメンテル
ドランテス、ヘルトゥルディス ロハス
ウェルタ、ガリンド、ビビアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Genetic Engineering and Biotechnology
Original Assignee
Center for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Genetic Engineering and Biotechnology filed Critical Center for Genetic Engineering and Biotechnology
Publication of JP2023548205A publication Critical patent/JP2023548205A/ja
Publication of JP2023548205A5 publication Critical patent/JP2023548205A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023527114A 2020-11-04 2021-11-03 コロナウイルススパイクタンパク質の受容体結合ドメインを含むキメラタンパク質及びその組成物 Pending JP2023548205A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2020-0081 2020-11-04
CU2020000081A CU24665B1 (es) 2020-11-04 2020-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden
PCT/CU2021/050010 WO2022096039A1 (es) 2020-11-04 2021-11-03 Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden

Publications (2)

Publication Number Publication Date
JP2023548205A true JP2023548205A (ja) 2023-11-15
JP2023548205A5 JP2023548205A5 (enExample) 2024-09-13

Family

ID=79164940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527114A Pending JP2023548205A (ja) 2020-11-04 2021-11-03 コロナウイルススパイクタンパク質の受容体結合ドメインを含むキメラタンパク質及びその組成物

Country Status (12)

Country Link
US (1) US20230405106A1 (enExample)
EP (1) EP4242222A1 (enExample)
JP (1) JP2023548205A (enExample)
CN (1) CN116802194A (enExample)
AR (1) AR123998A1 (enExample)
AU (1) AU2021373188A1 (enExample)
CA (1) CA3197024A1 (enExample)
CO (1) CO2023004963A2 (enExample)
CU (1) CU24665B1 (enExample)
MX (1) MX2023005211A (enExample)
WO (1) WO2022096039A1 (enExample)
ZA (1) ZA202304779B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7887978B2 (ja) * 2022-05-23 2026-07-10 バクスディグム カンパニー，リミティド ウイルスヌクレオカプシドを用いた結晶性タンパク質ベースの標的タンパク質融合自己組織化ナノ粒子製造プラットフォーム
KR102617592B1 (ko) * 2022-05-23 2023-12-29 주식회사 백스다임 바이러스 뉴클레오캡시드를 이용한 오량체형 독소 단백질 기반 목적 단백질 융합 오량체 제조 플랫폼

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111366734A (zh) * 2020-03-20 2020-07-03 广州市康润生物科技有限公司 双指标筛选新冠病毒及预判重型肺炎的方法
CN111620952A (zh) * 2020-06-17 2020-09-04 苏州米迪生物技术有限公司 基于嵌合型病毒样颗粒的新型冠状病毒疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗
CN111676248A (zh) * 2020-07-02 2020-09-18 军事科学院军事医学研究院军事兽医研究所 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111366734A (zh) * 2020-03-20 2020-07-03 广州市康润生物科技有限公司 双指标筛选新冠病毒及预判重型肺炎的方法
CN111620952A (zh) * 2020-06-17 2020-09-04 苏州米迪生物技术有限公司 基于嵌合型病毒样颗粒的新型冠状病毒疫苗

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 183, JPN6025033726, 2020, pages 1367 - 1382, ISSN: 0005666081 *
J. CLIN. VIROL., vol. 38, JPN6025033722, 2007, pages 49 - 56, ISSN: 0005666079 *
J. MED. CHEM., vol. 50, JPN6025033721, 2007, pages 5620 - 5626, ISSN: 0005666078 *
J. NANOBIOTECHNOL., vol. 16, no. 39, JPN6025033727, 2018, pages 1 - 21, ISSN: 0005666082 *
SCIENTIFIC REPORTS, vol. 10, no. 18149, JPN6025033724, 2020, pages 1 - 13, ISSN: 0005666080 *

Also Published As

Publication number Publication date
ZA202304779B (en) 2024-09-25
CO2023004963A2 (es) 2023-06-20
CA3197024A1 (en) 2022-05-12
CU24665B1 (es) 2023-06-13
CU20200081A7 (es) 2022-06-06
AU2021373188A1 (en) 2023-06-01
CN116802194A (zh) 2023-09-22
AR123998A1 (es) 2023-02-01
US20230405106A1 (en) 2023-12-21
WO2022096039A1 (es) 2022-05-12
EP4242222A1 (en) 2023-09-13
AU2021373188A9 (en) 2024-10-10
MX2023005211A (es) 2023-05-16

Similar Documents

Publication Publication Date Title
JP7566315B2 (ja) コンフォメーションが安定化されたｒｓｖ融合前ｆタンパク質
US10421789B2 (en) Engineered outer domain (EOD) of HIV GP120 and mutants thereof
JP2021519596A (ja) フェリチンタンパク質
JP2024038345A (ja) 抗原性ｏｓｐａポリペプチド
JP2011521662A5 (enExample)
JP2021519597A (ja) 抗原性呼吸器合胞体ウイルスポリペプチド
US20230086093A1 (en) Mutant rsv f protein and use thereof
McGaughey et al. Progress towards the development of a HIV-1 gp41-directed vaccine
EP4242222A1 (en) Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising them
CN104507496B (zh) 包含与crm197载体蛋白偶联的hiv gp41肽的免疫原性化合物
AU2022366884A1 (en) Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing
JP4202574B2 (ja) ｇｐ１２０に親和性を有するぺプチド
US20190194278A1 (en) Novel immunostimulating peptides
US20220372079A1 (en) Resurfaced dengue virus and ziki virus glycoprotein e diii variants and uses thereof
JP5785542B2 (ja) ワクチン
JP2010500407A (ja) Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法
JP4203082B2 (ja) ｇｐ１２０に親和性を有するぺプチド
JPH10182696A (ja) ｇｐ１２０に対して親和性を有するペプチド
JP2004509846A (ja) 肝炎ｃ型ウイルスコンジュゲート
JPH10182695A (ja) ｇｐ１２０に対して親和性を有するペプチド
Ramirez Engineering Protein-Based Nanoparticles for Infectious Disease Vaccine Development
JP2006328071A5 (enExample)
CN121311240A (zh) 基于dna折纸技术的亚单位疫苗
EA052740B1 (ru) Иммуногенные слитые белки коронавируса и связанные с ними способы
CN116964104A (zh) 免疫原性冠状病毒融合蛋白及相关方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240905

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260206